high-risk neuroblastoma

People with recurrent or progressive high-risk neuroblastoma subjects are asked to participate in a research study being conducted by Cohen Children’s Medical Center of NY.

You may be eligible to participate in this study if you:

• Have diagnosis of iobenguane avid, high-risk neuroblastoma
• May have had prior 131I-MIBG therapy
• Have acceptable liver and cardiac function, as well as coagulation function
• Have normal thyroid function
• Have full recovery from the toxic effects of any prior therapy

You may NOT participate in this study if you:

• Have received radiation for a minimum of 2 weeks prior. A minimum of 12 weeks prior to study enrollment is required following prior large field radiation therapy
• have received an antibody-based immunotherapy within 5 half-lives prior
• have received myeloablative therapy with autologous stem cell transplant within 12 weeks prior
• Have had an allogeneic stem cell treatment less than 4 months from Visit 1
• Have history of total body irradiation
• Are on hemodialysis
• Have clinically important cardiac, pulmonary, or hepatic impairment
• have reduced kidney function
• Are receiving Coumadin
• are receiving medications that can prolong QT interval
• have a history of deep vein thrombosis
• have received valproic acid within 30 days prior
• Have known immunodeficiency virus (HIV) infection, or active hepatitis B, or C infections
• Are pregnant or breastfeeding

Contact Information
Evangelina Atsidaftos, Study Coordinator
270-05 76th Avenue
New Hyde Park, NY 11040
Email: eatsidaf@northwell.edu